Publications

Export 115 results:
Author Title [ Type(Desc)] Year
Filters: Author is Pedro Rosa-Neto  [Clear All Filters]
Journal Article
Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim H-I, Gauthier S, Pellerin L, Hamel E, Rosa-Neto P.  2017.  [(18)F]FDG PET signal is driven by astroglial glutamate transport.. Nat Neurosci. 20(3):393-395.
Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, Tissot C, Qureshi MNaveed Iqb, Kang MSu, Mathotaarachchi S et al..  2020.  18F-MK-6240 PET for early and late detection of neurofibrillary tangles.. Brain. 143(9):2818-2830.
Levy JP, Bezgin G, Savard M, Pascoal TA, Finger E, Laforce R, Sonnen JA, Soucy J-P, Gauthier S, Rosa-Neto P et al..  2021.  18F-MK-6240 tau-PET in genetic frontotemporal dementia.. Brain.
Pascoal TA, Mathotaarachchi S, Shin M, Park AYeon, Mohades S, Benedet AL, Kang MSu, Massarweh G, Soucy J-P, Gauthier S et al..  2018.  Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.. Eur J Nucl Med Mol Imaging. 45(6):1021-1030.
Kang MSu, Aliaga AAliaga, Shin M, Mathotaarachchi S, Benedet AL, Pascoal TA, Therriault J, Chamoun M, Savard M, Devenyi GA et al..  2020.  Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease.. Mol Psychiatry.
Therriault J, Pascoal TA, Sefranek M, Mathotaarachchi S, Benedet AL, Chamoun M, Lussier FZ, Tissot C, Bellaver B, Lukasewicz PS et al..  2021.  Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia.. Ann Clin Transl Neurol. 8(10):2083-2092.
Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, Wang S, Beaudry T, Kang MS, Soucy J-P et al..  2016.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
Ongali B, Nicolakakis N, Tong X-K, Aboulkassim T, Papadopoulos P, Rosa-Neto P, Lecrux C, Imboden H, Hamel E.  2014.  Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.. Neurobiol Dis. 68:126-36.
Therriault J, Ng KPin, Pascoal TA, Mathotaarachchi S, Kang MSu, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V et al..  2018.  Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.. Neurology. 90(11):e932-e939.
Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S.  2016.  Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, Thomas É, Kang MSu, Lussier F, Tissot C et al..  2020.  APOEε4 potentiates the relationship between amyloid-β and tau pathologies.. Mol Psychiatry.
Picard C, Nilsson N, Labonte A, Auld D, Rosa-Neto P, Ashton NJ, Zetterberg H, Blennow K, Breitner JCS, Villeneuve S et al..  2021.  Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease.. Alzheimers Dement.
Boyle AJ, Gaudet VC, Black SE, Vasdev N, Rosa-Neto P, Zukotynski KA.  2021.  Artificial intelligence for molecular neuroimaging.. Ann Transl Med. 9(9):822.
Tissot C, Therriault J, Pascoal TA, Chamoun M, Lussier FZ, Savard M, Mathotaarachchi SS, Benedet AL, Thomas EM, Parsons M et al..  2021.  Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease.. Alzheimers Dement (N Y). 7(1):e12154.
Miron J, Picard C, Lafaille-Magnan M-E, Savard M, Labonte A, Breitner JCS, Rosa-Neto P, Auld D, Poirier J.  2019.  Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.. Alzheimers Dement. 15(7):951-960.
Bellaver B, Ferrari-Souza JPedro, da Ros LUglione, Carter SF, Rodriguez-Vieitez E, Nordberg A, Pellerin L, Rosa-Neto P, Leffa DTeixeira, Zimmer ER.  2021.  Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis.. Neurology.
Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER.  2019.  Astrocyte Biomarkers in Alzheimer's Disease.. Trends Mol Med.
Gauthier S, Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedetti AL, Shin M, Kang MSu, Li X, Ba M et al..  2017.  Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P et al..  2019.  Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.. Nat Commun. 10(1):2240.
Meyer P-F, Savard M, Poirier J, Labonte A, Rosa-Neto P, Weitz TM, Town T, Breitner JCS.  2018.  Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.. J Alzheimers Dis. 63(2):577-590.
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
DuBois JM, Rousset OG, Rowley J, Porras-Betancourt M, Reader AJ, Labbe A, Massarweh G, Soucy J-P, Rosa-Neto P, Kobayashi E.  2016.  Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET.. Eur J Nucl Med Mol Imaging. 43(1):152-62.
Li X, Ba M, Ng KPin, Mathotaarachchi S, Pascoal TA, Rosa-Neto P, Gauthier S.  2018.  Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.. Alzheimers Dement (Amst). 10:12-21.
Favier M, Janickova H, Justo D, Kljakic O, Runtz L, Natsheh JY, Pascoal TA, Germann J, Gallino D, Kang J-I et al..  2020.  Cholinergic dysfunction in the dorsal striatum promotes habit formation and maladaptive eating.. J Clin Invest. 130(12):6616-6630.
Sheynin Y, Rosa-Neto P, Hess RF, Vaucher E.  2020.  Cholinergic Modulation of Binocular Vision.. J Neurosci. 40(27):5208-5213.

Pages